This unit comprises the straightforward synthesis of protected 2'-deoxyribonucleoside-O-methyl-(H)-phosphinates in both 3'- and 5'-series. These compounds represent a new class of monomers compatible with the solid-phase synthesis of oligonucleotides using H-phosphonate chemistry and are suitable for the preparation of both 3'- and 5'-O-methylphosphonate oligonucleotides. The synthesis of 4-toluenesulfonyloxymethyl-(H)-phosphinic acid as a new reagent for the preparation of O-methyl-(H)-phosphinic acid derivatives is described. © 2017 by John Wiley & Sons, Inc.

Department of Bioorganic and Medicinal Chemistry Institute of Organic Chemistry and Biochemistry of the CAS Prague Czech Republic

Zobrazit více v PubMed

Crooke, S. T., & Geary, R. S. (2013). Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. British Journal of Clinical Pharmacology, 76, 269-276. doi: 10.1111/j.1365-2125.2012.04469.x.

Dean, N. M., & Bennett, C. F. (2003). Antisense oligonucleotide-based therapeutics for cancer. Oncogene, 22, 9087-9096. doi: 10.1038/sj.onc.1207231.

Ellington, A., & Pollard, J. D. (2001). Introduction to the synthesis and purification of oligonucleotides. Current Protocols in Nucleic Acid Chemistry, 00, A.3C.1-A.3C.22. doi: 10.1002/0471142700.nca03cs00.

Kole, R., Krainer, A. R., & Altman, S. (2012). RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nature Reviews Drug Discovery, 11, 125-140. doi: 10.1038/nrd3625.

Kostov, O., Páv, O., Buděšínský, M., Liboska, R., Šimák, O., Petrová, M., … Rosenberg, I. (2016). 4-Toluenesulfonyloxymethyl-(H)-phosphinate: A reagent for the introduction of O- and S-methyl-(H)-phosphinate moieties. Organic Letters, 18, 2704-2707. doi: 10.1021/acs.orglett.6b01167.

Marwick, C. (1998). First “antisense” drug will treat CMV retinitis. Journal of the American Medical Association, 280, 871. doi: 10.1001/jama.280.10.871-JMN0909-6-1.

Minshull, J., & Hunt, T. (1986). The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Research, 14, 6433-6451. doi: 10.1093/nar/14.16.6433.

Prakash, T. P., Siwkowski, A., Allerson, C. R., Migawa, M. T., Lee, S., Gaus, H. J., … Bhat, B. (2010). Antisense oligonucleotides containing conformationally constrained 2′,4′-(N-Methoxy)aminomethylene and 2′,4′-aminooxymethylene and 2′-O,4′-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. Journal of Medicinal Chemistry, 53, 1636-1650. doi: 10.1021/jm9013295.

Rejman, D., Masojídkovaá, M., & Rosenberg, I. (2004). Nucleosidyl-O-methylphosphonates: A pool of monomers for modified oligonucleotides. Nucleosides, Nucleotides Nucleic & Acids, 23, 1683−1705. doi: 10.1081/NCN-200033912.

Šípová, H., Špringer, T., Rejman, D., Šimák, O., Petrova, M., Novak, P., … Homola, J. (2014). 5′-O-Methylphosphonate nucleic acids-New modified DNAs that increase the Escherichia coli RNase H cleavage rate of hybrid duplexes. Nucleic Acids Research, 42, 5378−5389. doi: 10.1093/nar/gku125.

Southwell, A. L., Skotte, N. H., Bennett, C. F., & Hayden, M. R. (2012). Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine, 18, 634-643. doi: 10.1016/j.molmed.2012.09.001.

Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., … Thornton, C. A. (2012). Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature, 488, 111-115. doi: 10.1038/nature11362.

Solid-Phase Synthesis of Phosphorothioate/Phosphonothioate and Phosphoramidate/Phosphonamidate Oligonucleotides